The INTERCEPT project aims to build a blood risk score that can identify individuals with a high risk of developing Crohn disease within 5 years of initial evaluation.

FDA Approves Lilly’s Mirikizumab-mrkz for Crohn’s Disease

By Patient Care Staff

January 16th 2025

Marketed as Omvoh, the therapy is already approved as a first-in-class treatment for moderately to severely active ulcerative colitis.

January Issue of Patient Care Online Digital Edition is Now Live

By Sydney Jennings

December 16th 2024

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

Intervention Cuts Alcohol Use in Youths with Chronic Medical Conditions: Daily Dose

By Sydney Jennings

August 7th 2024

Your daily dose of the clinical news you may have missed.

<1 2 3

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777